Advertisement
Singapore markets open in 6 hours 55 minutes
  • Straits Times Index

    3,322.08
    -8.69 (-0.26%)
     
  • S&P 500

    5,358.84
    +11.85 (+0.22%)
     
  • Dow

    38,837.05
    +38.06 (+0.10%)
     
  • Nasdaq

    17,193.82
    +60.70 (+0.35%)
     
  • Bitcoin USD

    69,985.00
    +338.82 (+0.49%)
     
  • CMC Crypto 200

    1,450.28
    +3.61 (+0.25%)
     
  • FTSE 100

    8,228.48
    -16.89 (-0.20%)
     
  • Gold

    2,330.20
    +5.20 (+0.22%)
     
  • Crude Oil

    77.60
    +2.07 (+2.74%)
     
  • 10-Yr Bond

    4.4750
    +0.0450 (+1.02%)
     
  • Nikkei

    39,038.16
    +354.23 (+0.92%)
     
  • Hang Seng

    18,366.95
    -109.85 (-0.59%)
     
  • FTSE Bursa Malaysia

    1,614.37
    -3.49 (-0.22%)
     
  • Jakarta Composite Index

    6,921.55
    +23.60 (+0.34%)
     
  • PSE Index

    6,458.64
    -60.12 (-0.92%)
     

Co-Diagnostics First Quarter 2024 Earnings: Misses Expectations

Co-Diagnostics (NASDAQ:CODX) First Quarter 2024 Results

Key Financial Results

  • Net loss: US$9.31m (loss widened by 62% from 1Q 2023).

  • US$0.31 loss per share (further deteriorated from US$0.20 loss in 1Q 2023).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Co-Diagnostics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 85%. Earnings per share (EPS) also missed analyst estimates by 48%.

The company's shares are down 12% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Co-Diagnostics has 3 warning signs (and 1 which is concerning) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.